Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2011-03-29
2011-03-29
Leavitt, Maria (Department: 1633)
Chemistry: molecular biology and microbiology
Vector, per se
C435S252300, C435S455000, C435S456000, C536S023100, C536S023720
Reexamination Certificate
active
07915035
ABSTRACT:
The invention concerns a vaccine that can induce protection against disease especially in consequence of a lentivirus infection, especially an infection with the Feline Leukosis virus. Such vaccine comprises codon-optimized DNA sequences encoding structural proteins and the most important membrane protein of FeLV.
REFERENCES:
patent: 6248582 (2001-06-01), Khan et al.
patent: 6348196 (2002-02-01), Audonnet et al.
patent: 6696291 (2004-02-01), Shiver et al.
patent: 0216564 (1987-04-01), None
patent: WO 92/15672 (1992-09-01), None
patent: WO 98/21322 (1998-05-01), None
patent: WO 00/15824 (2000-03-01), None
patent: WO 03/031470 (2003-04-01), None
Flynn Jn, et al., Feline leukaemia virus: protective immunity is mediated by virus-specific cytotoxic T lymphocytes.Immunology. Sep. 2000;101(1):120-5.
www.kazusa.or.jp/codon/cgi-bin/showcodon.cgi?species=11824.
Kennell, Principles and practices of nucleic acid hybridization. Progr. Nucleic Acid Res. Mol. Biol. 11: 259-301, 1971.
Schirmbeck et al., Priming of immune responses to hepatitis B surface antigen with minimal DNA expression constructs modified with a nuclear localization signal peptide. J Mol Med. Jun. 2001;79(5-6):343-50.
Laprevotte et al., Nucleotide sequence of the gag gene and gag-pol junction of feline leukemia virusJ. Virol. 50 (3), 884-894 (1984) and Genbank Accession No., K01803, FeLV gag cDNA.
www.kazusa.or.jp/codon/cgi-bin/showcodon.cgi?species=11824 . 2002.
“Protection of Cats Against Feline Leukemia Virus by Vaccination With a Canarypdx Virus Recombinant, ALVAC-FL,” Tartaglia et al., Journal of Virology, Apr. 1993, p. 2370-2375, vol. 67, No. 4.
“Development of a Genetically Engineered Vaccine Against Feline Leukemia Virus Infection,” Kensil et al., Javma, vol. 199, No. 10, Nov. 15,1991, p. 1423-1427.
“New Hope for an Aids Vaccine,” H.L. Robinson, Nature Reviews, Immunology, vol. 2, Apr. 2002, p. 239-250.
“Increased Expression and Immunogenicity of Sequence-Modified Human Immunodeficiency Virus Type 1 Gag Gene,” Megede et al., Journal of Virology, Mar. 2000, p. 2628-2635, vol. 74, No. 6.
“Human Immunodeficiency Virus Type 1-Specific Immunity After Genetic Immunization Is Enhanced by Modification of Gag and Pol Expression,” Huang et al., Journal of Virology, May 2001, p. 4947-4951, vol. 75, No. 10.
“Feline Leukaemia Virus: Protective Immunity Is Mediated by Virus-Specific Cytotoxic T Lymphocytes,” Flynn et al., Immunology 2000, 101, p. 120-125.
Juhls Christiane
Junghans Claas
Lutz Hans
Oswald Detlef
Schroff Matthias
Day Ursula B.
Feiereisen Henry M.
Leavitt Maria
Mologen AG
LandOfFree
Vaccine against oncovirus infections such as infections by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vaccine against oncovirus infections such as infections by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccine against oncovirus infections such as infections by... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2680497